Abstract
An increasing number of patients receive anticoagulant therapy to prevent and treat arterial or venous thromboembolism. The major complication of anticoagulant therapy is the increase of the individual bleeding risk. All anticoagulant drugs can cause haemorrhages, that can sometimes be life-threatening. Although heparins and the vitamin K antagonists have been the most widely used anticoagulants for decades, the correct management of bleeding complications associated with these agents has been poorly studied. More recently, new anticoagulant drugs, both parenteral and oral, have been approved for clinical use. Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event. The aim of this article is to describe the haemorrhagic risk and the management of bleeding complications associated with the principal anticoagulant drugs.
Keywords: Anticoagulants, bleeding, vitamin k antagonists, dabigatran, rivaroxaban, heparin, fondaparinux, venous thromboembolism, anticoagulant therapy, heparins, transfusion, Thrombosis, Hemostasis, Interna-tional normalized Ratio, VKA, hepatic disease, hypertension, malignancy, haematological disease, thromboembolic risk, VKAs therapy, INR monitoring, American College of Chest Physicians, warfarin therapy, acenocoumarol, phenopro-coumon, Antifibrinolytic drugs, tranexamic acid, fresh frozen plasma, recombinant factor VIIa, Prothrombin Complex Concentrates, liver disease, haemophilia, anti-Xa activity, Protamine Sulfate
Current Pharmaceutical Design
Title: Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants
Volume: 16 Issue: 31
Author(s): Erica Romualdi, Elena Rancan, Sergio Siragusa and Walter Ageno
Affiliation:
Keywords: Anticoagulants, bleeding, vitamin k antagonists, dabigatran, rivaroxaban, heparin, fondaparinux, venous thromboembolism, anticoagulant therapy, heparins, transfusion, Thrombosis, Hemostasis, Interna-tional normalized Ratio, VKA, hepatic disease, hypertension, malignancy, haematological disease, thromboembolic risk, VKAs therapy, INR monitoring, American College of Chest Physicians, warfarin therapy, acenocoumarol, phenopro-coumon, Antifibrinolytic drugs, tranexamic acid, fresh frozen plasma, recombinant factor VIIa, Prothrombin Complex Concentrates, liver disease, haemophilia, anti-Xa activity, Protamine Sulfate
Abstract: An increasing number of patients receive anticoagulant therapy to prevent and treat arterial or venous thromboembolism. The major complication of anticoagulant therapy is the increase of the individual bleeding risk. All anticoagulant drugs can cause haemorrhages, that can sometimes be life-threatening. Although heparins and the vitamin K antagonists have been the most widely used anticoagulants for decades, the correct management of bleeding complications associated with these agents has been poorly studied. More recently, new anticoagulant drugs, both parenteral and oral, have been approved for clinical use. Currently, none of these new agents has a specific antidote, and little advise can be given on how to manage a major bleeding event. The aim of this article is to describe the haemorrhagic risk and the management of bleeding complications associated with the principal anticoagulant drugs.
Export Options
About this article
Cite this article as:
Romualdi Erica, Rancan Elena, Siragusa Sergio and Ageno Walter, Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563329
DOI https://dx.doi.org/10.2174/138161210793563329 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design Antisense DNA and RNA: Potential Therapeutics for Viral Infection
Anti-Infective Agents in Medicinal Chemistry Reactive Species, Cellular Repair and Risk Factors in the Onset of Type 2 Diabetes Mellitus: Review and Hypothesis
Current Diabetes Reviews Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Ganoderma lucidum (Ling-zhi): The Impact of Chemistry on Biological Activity in Cancer
Current Bioactive Compounds Antimicrobial Agents-Associated with QT Interval Prolongation
Current Drug Safety From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium
Current Vascular Pharmacology Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design Modulators of the Vascular Endothelin Receptor in Blood Pressure Regulation and Hypertension
Current Molecular Pharmacology Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Differential Effects of Trans and Polyunsaturated Fatty Acids on Ischemia/ Reperfusion Injury and its Associated Cardiovascular Disease States
Current Pharmaceutical Design Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Effects of Low Doses of Polyunsaturated Fatty Acids on the Attention Deficit/Hyperactivity Disorder of Children: A Systematic Review
Current Neuropharmacology Smoking and Congenital Heart Disease: The Epidemiological and Biological Link
Current Pharmaceutical Design The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Current Clinical Pharmacology Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Spices: Therapeutic Potential in Cardiovascular Health
Current Pharmaceutical Design Recent Advances in Ozonation of Vegetable Oils
Recent Patents on Materials Science